News

The compounds are orally active, selective and reversible inhibitors of monoamine oxidase-B (MAO-B). They have favourable preclinical profiles, and were well tolerated and showed excellent pharmacokinetic properties in

This application is the first marketing approval submission for Orapem worldwide, and the first NDA submission the company has made. The Orapem submission is primarily based on data

The NDA submission is based on the results of 11 clinical trials, involving more than 1300 patients and subjects including two multi-center phase III clinical trials conducted in

Fay Guarraci, assistant professor of psychology at Southwestern University, and Stacey Benson, a 2005 Southwestern graduate, gave 108 female rats a moderate dose of caffeine before a mating

Under the research collaboration, Roche will use its screening capabilities to investigate three mutually agreed targets in the field of inflammatory diseases. Amira will then utilize its expertise

The 200 patient study is designed to assess both the safety of Androxal and its efficacy in restoring normal pituitary and testicular function in men that are hypogonadal

More than 300 patients enrolled in the trial to evaluate the efficacy of daily administration of the drug as treatment for the abnormal fat accumulation and distribution associated

This approval of the intravenous form of the drug will provide an alternative for patients who have difficulty with oral bisphosphonate dosing requirements, including an inability to sit

Cangen has commenced patient recruitment for a study at clinical sites in Asia and will receive funding from Olympus in support of the study and ongoing research and